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Invasive Candida Infections in Liver Transplant
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Background. Invasive fungal infections remain a leading cause of morbidity and mortality among liver transplant recipients
(LTRs). In this patient population, invasive Candida infections (ICIs) account for the largemajority of cases. To date, only small stud-
ies and case-series analysing clinical presentation and risk factors for mortality in LTRs with ICIs are available.Methods.We per-
formed a retrospective multicenter multinational study in 10 centers in Europe and Brazil. All consecutive LTRs developing ICIs
during the period January 2011 to December 2013were included in the study.Results.A total of 42 LTRswere included.Median
agewas 52.5 years, and 78.6%of patients weremen. Viral hepatitis was themost common cause for liver transplantation (42.9%).
Candidemia represented the majority of cases (24, 57.1%), followed by intra-abdominal candidiasis (18, 42.9%). Overall 30-day
mortality was 23.8%, with higher mortality in patients with candidemia compared with intra-abdominal candidiasis (37.5% vs
5.6%, P = 0.02). Multivariate analysis showed candidemia to be a risk factor associated with mortality among LTRs presenting ICIs
(odds ratio, 11.86; 95% confidence interval, 1.5-280; P = 0.01). Candida albicans represented the most common isolate (59.5%).
High rates of antifungal resistances were found, with 16.7% and 4.8% of isolates displaying resistance to azoles and caspofungin,
respectively. Conclusions. Our study confirms the occurrence of high mortality rates in LTRs developing ICIs. Mortality rates
varied according to the type of infection, with candidemia representing a risk factor for mortality. The high rates of antifungal resis-
tance should be considered in the choice of the empiric antifungal regimen.
(Transplantation Direct 2017;3: e156; doi: 10.1097/TXD.0000000000000673. Published online 18 April, 2017.)
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Invasive fungal infections (IFIs),mainly represented by invasiveCandida infections (ICIs) and invasive aspergillosis, repre-
sent a frequent complication and a leading cause of morbid-
ity and mortality among liver transplant recipients (LTRs).1-3
The introduction of antifungal prophylaxis after liver
transplantation has demonstrated to be effective in reducing
both incidence and IFIs-related mortality when 1 or more
specific risk factors are present4; however, risk factors are
not well defined and a consensus regarding which patients
should receive antifungal prophylaxis after liver transplan-
tation does not exist so far, with an overall incidence of IFIs
of approximately 5% to 7% still reported, irrespective of
antifungal prophylaxis.5,6 Among IFIs occurring after liver
transplantation, ICIs account for up to 75% of cases, with
prolonged or repeated surgery, choledochojejunostomy, re-
transplantation, dialysis, prolonged antibiotic treatment and
hospitalization, cytomegalovirus disease, and Candida colo-
nization reported as common risk factors.4-6 ICIs usually oc-
cur within the first 3 months after liver transplantation and
are associated with overall mortality rates up to 70%.1,7,8
Despite these alarming figures, only few studies focusing on
ICIs in LTRs have been reported. The aim of our study was
to describe characteristics, outcome, and risk factors formor-
tality in LTRs developing ICIs.
MATERIALS AND METHODS
Patient Population and Study Design
Amulticenter, multinational retrospective cohort study was
conducted across 10 centers in Europe (Italy, Spain, Ireland,
and Belgium) and Brazil over a 3-year period (2011–2013)
(Table 1). All consecutive LTRs developing an episode of ICI
during the study period were included. No center performed
universal antifungal prophylaxis for LTRs.
The study was approved by the institutional review board
of the coordinating center (Udine University Hospital, Italy)
and written patient consent was not required because of the
observational nature of this study.
Patients’ baseline characteristics and infection-related var-
iables were collected from the hospital medical records,
microbiology databases, and pharmacy databases of the par-
ticipating centers.
The following data were recorded: age, sex, comorbidities,
etiology of liver disease, surgical and medical complications
after liver transplant, prior interventions (eg, abdominal sur-
gery, vascular or abdominal device placement), prior antibiotic
(more than 7 days in the past 30 days) or azole exposure (in
the past 30 days), receipt of antifungal prophylaxis after liver
transplantation, parenteral nutrition and/or immunosup-
pressant administration and recurrence of cirrhosis after liver
transplant, including the degree of severity.
Definitions
Candidemia was defined as the isolation of Candida spp.
from at least 1 blood culture, according with the current
guidelines.9
An episode of intra-abdominal candidiasis (IAC) was de-
fined as follows:
• Candida detection by directmicroscopy examination or growth
in culture from purulent or necrotic intra-abdominal speci-
mens obtained during surgery or by percutaneous aspiration;
• Candida growth from bile, intra-biliary ducts devices, and bi-
opsy of intra-abdominal organs;
• Candida growth from blood cultures in clinical setting of
secondary and tertiary peritonitis;
• Candida growth from drainage tubes only if placed less than
24 hours before the cultures10;
Child-Pugh score and model for end-stage liver disease
(MELD) score have been calculated for patients with recur-
rence of liver cirrhosis after transplantation. Infections were
classified as community-acquired, health care–associated and
hospital-acquired according with Friedman criteria.11 Setting
of acquisition and time between transplant and infec-
tion onset were recorded. Clinical presentation, in particular
the presence of fever (T > 38°C), septic shock and Sequen-
tial Organ Failure Assessment (SOFA) score, was recorded.
Septic shock was defined according to current guidelines.12
Microbiological data analyzed included Candida species
and antifungal susceptibility to fluconazole, voriconazole,
echinocandins, and amphotericin B. Treatment-related char-
acteristics examined were timing of adequate antifungal
treatment relative to blood or abdominal samples cultures
positivity, type of antifungal prescribed as initial treatment
and adequate source control. Antifungal therapywas consid-
ered adequate if the organism was shown to be susceptible to
the prescribed antifungal treatment and the dosage of anti-
fungal was adequate. The following antifungal dosages were
TABLE 1.
Centers included with local incidence of ICIs
Name of center, city Country No. ICI episodes
Total number of
liver transplants (2011-2013)
Incidence in the
study period (2011-2013)
AOU Molinette, Torino Italy 6 240 2.5%
AOU SMM, Udine Italy 1 90 1.1%
AOU Pisana, Pisa Italy 7 325 2.15%
San Martino IST, Genova Italy 1 0 (not a transpant center)
Policlinico Gemelli, Roma Italy 1 86 1.16%
Val d’Hebron Hospital, Barcelona Spain 3 82 3.7 %
Gregorio Maranon, Madrid Spain 9 109 8.2%
University Hospital Leuven, Leuven Belgium 10 211 4.7%
Sant James Hospital, Dublin Ireland 1 0 (Not a transplant center)
San Paolo University, San paolo Brazil 3 65 4.6%
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considered adequate: fluconazole 800 mg loading dose (for
patients with bodymass index >30, 1200-1600mg) followed
by a daily dosage of at least 400 mg (600-800 mg for
body mass index > 30); liposomal amphotericin B (L-AmB),
3 mg/kg per day; amphotericin B lipid complex, 5 mg/kg
per day; caspofungin, 70 mg loading dose (100 mg) followed
by 50 mg/d; micafungin, 100 mg/d, anidulafungin 200 mg
loading dose followed by 100 mg/d. These dosages refer to
patients with normal hepatic and renal function. In case of
hepatic or renal impairment dose adjustment have been con-
sidered adequate according with the per package indications.
Source control was considered adequate in the following
cases: (1) devices or foreign bodies removal, (2) drainage of
infected fluid collections, (3) debridement of infected solid
tissue, (4) definitive measures to correct anatomic derange-
ments resulting in ongoingmicrobial contamination. The pri-
mary outcome variable was all-cause 30-day mortality.
Blood Cultures and Microbiology Analysis
Candida species were isolated using the BACTEC 860 sys-
tem (Becton-Dickinson, Inc., Sparks, MD) and BacT/Alert
3D (BioMérieux, Marcy-l'Étoile- France). The species were
identified using API ID 32C system (BioMérieux, Marcy-
l'Étoile- France) or Vitek 2 system (BioMérieux, Marcy-l'Étoile-
France). In case of inconclusive results by both systems, isolates
were definitively identified using supplemental tests, such
as presence or absence of well-formed pseudohyphae on
cornmeal-Tween 80 agar and growth at 42°C to 45°C. The
last test was also required to differentiate isolates ofCandida
albicans from those of Candida dubliniensis. Antifungal sus-
ceptibility testing to amphotericin B, caspofungin, fluconazole
and voriconazole was performed using the Sensititre YeasOne
colorimetric plate (Trek Diagnostics Systems, Cleveland, OH)
or by agar diffusion using E-test strips (BioMérieux, Marcy-
l'Étoile- France) and interpreted by the Clinical Laboratory
Standards Institute breakpoints.
Statistical Analysis
Continuous and categorical data were reported as mean
and SD or median, 25th and 75th percentile and frequency
distributions, respectively. Differences existed between groups
for continuous variables were evaluated through the Student
t test or, when appropriate, the median test. Categorical var-
iables were evaluated using chi-square or, when appropriate,
the 2-tailed Fisher exact test. Multiple logistic regression anal-
ysis was performed to identify risk factors that were associated
with 30-day hospital mortality (JMP, SAS, NC). Covariates
that were significant at 0.10 in the univariate analysis and
therapy-related variables were further evaluated for inclusion
in multivariable regressionmodels, using a backward stepwise
algorithm. Odds ratio and 95% confidence interval were re-
ported. All tests were 2-tailed, and a P value less than 0.05
was determined to represent statistical significance.
RESULTS
Patient’s Characteristics
Overall incidence of ICIs during the study period was
3.47% (Table 1). A total of 42 LTRs with ICIs were included
in the study. Clinical characteristics of patients included are
described in Table 2. Median age was 52.5 years and 78.6%
of patients were men. Viral hepatitis was the most common
cause for liver transplantation (42.9%), followed by alcohol
abuse (26.2%). The median number of days between trans-
plantation and infection onset was 151 days, with an inter-
quartile range of 14 to 1037 days. At the time of diagnosis 21
(50%) patients were hospitalized in intensive care unit (ICU),
8 (19%) in internal medicine ward, 6 (14.3%) in surgical
ward and 7 (16.7%) in other wards.
Among the classical risk factors for ICIs occurrence post-
OLT, reoperation was the most common (33.3%), followed
by choledochojejunostomy (23.8%) and prolonged operation
(>8 hours) (14.3%); less common were retransplantation
and the presence of an anastomotic leakage. Other factors
included the need for renal replacement therapy (26.2%),
transfusion of more than 40 units of cellular blood products
during the intervention (21.4%), organ rejection (16.7%),
and cytomegalovirus reactivation (>100.000 cp/mL) (9.5%).
A total of 10 (23.8%) patients received antifungal prophylaxis
after liver transplantation.Most patients were receiving an im-
munosuppressive treatment (92.9%) and/or steroids (61.9%)
at the time of cultures. Vascular devices and abdominal drain-
ages were frequent (80.9% and 47.6% of cases, respectively).
The large majority of patients (76.2%) had been recently
treated with antimicrobials and 19 (45.2%) were receiving
parenteral nutrition. Recurrence of liver cirrhosis after trans-
plantation was diagnosed in 19 (45.2%) patients at the time
of cultures; the majority of these patients were classified as
Child-Pugh C (36.8%), and MELD score was higher than
15 in 10 (52.6%) cases.
Clinical Presentation and Timing of Infection Onset
Candidemia accounted for the majority of ICIs cases (24,
57.1%), followed by IAC (18, 42.9%). Peritonitis and ab-
dominal abscesses were the most common types of IAC,
(38.9% in both cases), followed by biliary tract infections
(16.7%). A total of 11 (26.2%) patients presented with septic
shock and 14 (33.3%) were admitted to ICU after the onset
of the infection. Fever was present in 28 (66.7%) cases. Only
1 case of Candida blood cultures positivity was reported
among IAC cases.
In our cohort, about 34.1% and 46.3% cases of ICIs
occurred, respectively, during the first month and within
3 months after surgery. Patients with early (<3 months from
transplant) ICIs were more likely to be hospitalized in ICU
ward (68.4% vs 31.8%, P = 0.02) and to have acute renal
failure (50% vs 10%, P = 0.06). Late ICIs in LTRs was more
likely to be acquired in community (0% vs 27.3%, P = 0.03)
and in internal medicine wards setting (5.3% vs 31.8%,
P = 0.07). No si7gnificant differences were detected between
early and late IC regarding clinical presentation. Table S1,
SDC, http://links.lww.com/TXD/A38 reports the differences
between liver transplant patients presenting with early and
late ICIs.
Microbiology
Candida albicans was the most common species and was
isolated in 25 (59.5%) patients. Among nonalbicans Candida
spp., C. tropicalis was the most frequently isolated (11.9%),
followed byC. parapsilosis (7.1%),C. glabrata, andC. kruzei
(4.8% in both cases),C. dublinensis (2.4%), and only 4 (9.5%)
patients had a polyfungal infection. A total of 83.3%of Candida
strains were susceptible to fluconazole and voriconazole,
whereas 95.2% were susceptible to amphotericin B and to
© 2017 Wolters Kluwer Bassetti et al 3
TABLE 2.
Clinical characteristics, treatment, and clinical outcome of liver transplant patients with ICIs and comparison between
survivors and nonsurvivors
Characteristics N = 42 Survivors (n = 32) Nonsurvivors (n = 10) P
Age: median (IQR), y 52.5 (43-60) 52.5 (43-59) 55.5 (43-62.5) NS
Male, n (%) 33 (78.6%) 25/32 8/10 NS
Charlson score: median (IQR) 3.5 (2-5) 3.5 (1-5) 4 (1.5-6) NS
Comorbidities
Diabetesa 8 (19%) 7 (21.9%) 1 (10.0%) NS
Heart disease 3 (7.1%) 2 (6.3%) 1 (10.0%) NS
Dialitic renal failure 4 (9.5%) 3 (9.4%) 1 (10.0%) NS
Solid tumor 12 (28.6%) 9 (28.1%) 3 (30.0%) NS
COPD 1 (2.4%) 1 (3.1%) 0 (0.0%) NS
HIV infection 1 (2.4%) 1 (3.1%) 0 (0.0%) NS
Ward (at the time of cultures)
ICU 21 (50%) 12 (37.5%) 9 (90%) 0.004
Internal medicine 8 (19%) 7 (21.9) 1 (10) NS
Surgical ward 6 (14.3%) 6 (18.7) 0 (0) NS
Other 7 (16.7%) 7 (21.9) 0 (0) NS
Recurrence of cirrhosis 19 (45.2%) 14 (43.8) 5/10 (50) NS
Child-Pugh score at the time of cultures (N = 19)
A 6 (31.6%)
B 6 (31.6%)
C 7 (36.8%) 3 (9.4%) 4 (40.0%) 0.02
MELD score at the time of cultures (N = 19)
< 15 9 (47.4%)
15-25 3 (15.8%)
> 25 7 (36.8%) 3 (9.4%) 4 (40.0%) 0.02
Type of invasive candidiasis
Candidemia 24 (57.1%) 15 (46.9%) 9 (90.0%) 0.02
Abdominal candidiasis 18 (42.9%)
Setting of acquisition
Hospital-acquired 32 (76.2%) 22 (68.8%) 10 (100%) 0.04
Health care–associated 4 (9.5%)
Community-acquired 6 (14.3%)
Time between liver transplantation and infection onset: median (IQR), d 151 (14-1037) 150.5 (17.8-935.5) 387 (6.5-1250) NS
Vascular devices 34 (80.9%) 24 (75%) 10 (100%) NS
Abdominal devices 20 (47.6%) 17 (53.1%) 3 (30%) NS
Parenteral nutrition 19 (45.2%) 13 (40.6%) 6 (60%) NS
Recent antimicrobial therapy (>7 d in the previous 30 d) 32 (76.2%) 24 (75%) 8 (80%) NS
Prior azole exposure (in the previous 30 d) 8 (19%) 5 (15.6%) 3 (30%) NS
Steroid treatment (at least prednisone 10 mg/d for 30 d) 26 (61.9%) 20 (62.5%) 6 (60%) NS
Immunosuppressants 39 (92.9%) 30 (93.8%) 9 (90%) NS
Fever (T ≥ 38°C) 28 (66.7%) 20 (62.5%) 8 (80%) NS
SOFA score (at infection onset) (median, IQR) 4 (2-10.5) 3 (2-7) 11 (5-15) 0.008
Septic shock 11 (26.2%) 6 (18.8%) 5 (50.0%) <0.05
ICU admission after infection onset 14 (33.3%)
Adequate source control 27 (64.3%) 22 (81.5%) 5 (50%) NS
Adequate antifungal treatment (according to susceptibility test and dose) 35 (83.3%) 25 (78.1%) 10 (100%) NS
Initial antifungal treatment
Echinocandins 22 (52.4%) 17 (53.1%) 5 (50%) NS
Azole 15 (35.7%) 12 (37.5%) 3 (30%) NS
Amphotericin B 3 (7.1%) 1 (3.1%) 2 (20%) NS
None 2 (4.8%) 2 (6.3%) 0 (0%) NS
Continued next page
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caspofungin. Overall, 7 cases of fluconazole resistance and
2 cases of echinocandin resistance were reported. A total of
20 (47.6%) patients had a concomitant bacterial infection.
Antifungal Therapy
A total of 35 (83.3%) patients received an adequate anti-
fungal treatment according to susceptibility test and dose;
among these, antifungal treatment was prescribed within
24, 48, and 72 hours from cultures positivity in 40%, 20%,
and 17.1% of cases, respectively. Eight (22.9%) patients re-
ceived antifungal treatment after 72 hours. Echinocandins
were the most common antifungal agent prescribed as ini-
tial treatment (52.4%), followed by azoles (35.7%) and
amphotericin B (7.1%). An adequate source control was per-
formed in 27 (64.3%) patients within 24, 48, and 72 hours
from cultures positivity in 51.9%, 22.2%, and 11.1% of
cases, respectively.
Outcome and Risk Factors for Mortality
Overall 30-day mortality was 23.8%. Table 2 summarizes
the significant differences between patients who died within
30 days from the diagnosis of ICI compared with survivors
by univariate analysis. Patients who died were more fre-
quently admitted to ICU compared with survivors (90% vs
37.5%, P = 0.004), were more likely to present with septic
shock (50.0% vs 18.8%, P = <0.05), and had higher values
of SOFA score (11 vs 3, P = 0.008). Hospital-acquired infec-
tions were more common among nonsurvivor compared
with survivors (100% vs 68.8%, P = 0.04). Child-Pugh C
andMELD score greater than 25 were more frequent among
patients who died (40% vs 9.4%, P = 0.02 in both cases).
Candidemia was more common among nonsurvivors (90% vs
46.9%, P = 0.02). The isolation of C. tropicalis was more
common among nonsurvivors compared with survivors
(30% vs 6.25%, P = 0.05). No significant differences were
detected between survivors and nonsurvivors regarding
timing of adequate antifungal treatment and source control.
Moreover, a concomitant bacterial infection was not signifi-
cantly associatedwith increasedmortality.Multivariate anal-
ysis demonstrated that candidemia (odds ratio, 11.86; 95%
confidence interval, 1.5-280; P = 0.01) was a risk factor asso-
ciated with 30-day mortality in LTRs presenting with ICIs.
An increased risk for mortality associated with clinical pre-
sentation with septic shock and Child-Pugh C liver failure
was reported but did not reach statistical significance.
Comparison Between Liver Transplant Patients
Presenting With Candidemia or IAC
Table 3 reports the differences between liver transplant pa-
tients presenting with candidemia or IAC. Specifically, ICU
admission at the time of cultures and vascular device place-
ment were more common among patients with candidemia;
conversely, patients with IAC were more likely to have ab-
dominal devices placement, polyfungal infections andMELD
score < 15. No differences were detected in clinical presenta-
tionwith septic shock, but SOFA scorewas significantly higher
in patients with candidemia. Of note, in patients with IAC
lower rates of adequate antifungal treatment prescriptionwere
TABLE 2. (Continued)
Characteristics N = 42 Survivors (n = 32) Nonsurvivors (n = 10) P
Candida specie
C. albicans 25 (59.5%) 19 (59.4%) 6 (60%) NS
C. tropicalis 5 (11.9%) 2 (6.25%) 3 (30.0%) 0.05
C. parapsilosis 3 (7.1%) 2 (6.25%) 1 (10%) NS
C. glabrata 2 (4.8%) 2 (6.25%) 0 (0%) NS
C. kruzei 2 (4.8%) 2 (6.25%) 0 (0%) NS
C. dubliniensis 1 (2.4%) 1 (3.1%) 0 (0%) NS
More than 1 Candida 4 (9.5%) 4 (12.5%) 0 (0%) NS
Concomitant bacterial infection 20 (47.6%) 14 (43.8%) 6 (60%) NS
Duration of antifungal treatment: median (IQR), d 14 (10-30) 19.5 (10.5-34.8) 11 (7.8-22.5) NS
a 5% of patients were diagnosed of diabetes before transplantation.
Data are number of positive results/total number studied and (%).
COPD indicates chronic obstructive pulmonary disease; IQR, interquartile range.
TABLE 3.
Characteristics of LTRs presenting with candidemia (N = 24) compared with patients presenting with abdominal
candidiasis (N = 18)
Variables Candidemia Abdominal candidiasis P
ICU admission (at the time of cultures) 16/24 (66.7%) 5/18 (27.8%) 0.01
MELD score <15 (at the time of cultures)a 2/10 (20%) 7/9 (77.8%) 0.04
More than 1 Candida spp. isolation 0/24 (0%) 4/18 (72.2%) 0.02
Vascular devices 22/24 (91.7%) 12/18 (66.7%) 0.04
Abdominal devices 8/24 (33.3%) 12/18 (66.7%) 0.03
SOFA score: median (IQR) 8 (5-15) 2.5 (1.5-4.5) 0.001
Adequate antifungal treatment 23/24 (95.8%) 12/18 (66.7%) 0.01
Death (30 d) 9/24 (37.5%) 1/18 (5.6%) 0.02
a Among cirrhotic patients (N = 19).
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found (66.7% vs 95.8%, P = 0.01), with no significant differ-
ences regarding both adequacy and timing of source control.
However, significantly higher 30-day mortality rates were
reported in patients with candidemia compared with IAC
(37.5% vs 5.6%, P = 0.02).
DISCUSSION
ICIs have been associated with mortality rates ranging be-
tween 30% and 50% in the general population and up to
80% among critically ill patients.13,14 Data including LTRs,
however, are limited, showing large variability inmortality.7,15,16
We reported overall mortality of 23.8% with higher rates in
candidemia compared with IAC. To the best of our knowl-
edge, no study had previously investigated the relationship
between type of ICIs and clinical outcomes among LTRs.
These datawarrant, especially among patientswith candidemia,
prompt antifungal treatment along with a timely source con-
trol (eg, central venous catheter removal) to improve the pa-
tients’ outcome.
Our study showed overall mortality rates slightly lower
than those reported in the general population with IAC
(26.8%).17 Possible reasons include a limited number of sep-
tic shock at presentation and significantly, lower mean age,
that represented independent risk factors for mortality.17
Moreover, cardiovascular, pulmonary diseases, and diabetes,
that may be contraindications to perform a liver transplant,
were less common among LTRs compared with the general
population developing ICIs. Septic shock, in particular, has
been associated with mortality in up to 50% of patients with
candidemia,18 and is an independent risk factor for mortality
among patients with IAC.17 In our study, an increased risk
associated with septic shock at presentation was reported,
but statistical significancewas not achieved probably because
of the small number of patients included in this group.
Decompensated liver cirrhosis represents a risk factor for
the development of both bacterial and fungal infections18-20
and was present in 45.2% of patients in our study. Other re-
ports did not show these results, probably due to limited
follow-up times. In our study, median time between trans-
plantation and Candida infections was 5 months, and nearly
half of patients developed ICIs after 6 months from liver
transplant. Recurrence of decompensated cirrhosis after liver
transplant may therefore represent a risk factor for late oc-
currence of ICIs.
Our data confirmed C. albicans as the most common iso-
late.13,17 Isolation of nonalbicans species has been associated
with significantly higher mortality.21,22 We showed higher
mortality rates in C. tropicalis compared with other species,
with no differences between candidemia and IAC.
In patients with IC, the synergistic effect of timely treat-
ment adequacy and source control has shown to be crucial
and has impacted in the management of invasive candidiasis.
In our study, early (<24 hours) source control (51.9%) and
adequate antifungal therapy (83.3%)were achieved in a high
proportion of the patients. However, we did not observe a
clear effect adequate antifungal treatment (based on suscepti-
bility pattern and dosage of antifungals) and source control
on mortality rates. These results are probably related to the
relatively small sample size of our cohort, whichmay have in-
troduced a type II error in the statistical analysis.
Significant rates of both azole and echinocandin resistance
were reported in our study (16.7% and 4.8%, respectively).
Antifungal resistance in Candida spp. represents a rising
problem, even if a wide variability is present among different
countries and species, with overall resistance rates of flucon-
azole resistance of approximately 5% in C. albicans. Studies
in LTR reported overall rates of fluconazole resistance up
to 57%, attributed to the high rates of nonalbicans strains
and previous antifungal prophylaxis.21,22 Echinocandin re-
sistance, instead, is reported in less than 2% of Candida iso-
lates worldwide.23 Interestingly, only 23.8% of patients
received antifungal prophylaxis after liver transplantation,
and recent treatment with azoles was documented in 19%
of cases in our report without association with antifungal re-
sistance. The majority of cases of fluconazole-resistance and
both cases of echinocandin resistance were detected in IAC,
confirming recently reported data.24 IAC has been investi-
gated as a hidden reservoir for echinocandin-resistant strains,
particularly in patients with prolonged echinocandin expo-
sure and breakthrough infections.25 Overall, our results sug-
gest that LTRs are at risk for Candida infections, including
nonalbicans strains, with higher probability of fluconazole
and, less frequently, echinocandin resistance compared to the
general population. These factors, together with the knowl-
edge of local epidemiology, should be taken into account in
the management of ICIs in LTRs. In particular, risk factors
for fluconazole resistance should be considered when treating
empirically candidemia in LTR.
Echinocandins were the most commonly prescribed anti-
fungals in candidemia and IAC, similarly to other European
studies and according to recently published guidelines.17,18,26,27
In LTRs, in particular, echinocandins have demonstrated low
liver toxicity and limited drug-drug interactions compared
to azoles. These characteristics, together with a low probabil-
ity of antifungal resistance and the enhanced antibiofilm ac-
tivity, make echinocandins an effective empiric treatment in
this population.
Interestingly, in our study, an adequate antifungal treat-
ment was prescribed in only 66.7% of IAC compared with
95.8% of cases of candidemia. This percentage was similar
to the 1 reported in general population with IAC17 probably
due to the increased rates of fluconazole resistance reported.
No correlationwas found betweenmortality and adequate
antifungal treatment or source control, which has been found
to be independently correlated with clinical outcome both in
candidemia and in IAC.17,18
In conclusion, our study highlights high mortality rates
associatedwith candida infections, especially candidemia, among
liver transplant patients. In this setting, the choice of an ade-
quate therapy is paramount, and risk factors for fluconazole
resistance should be taken into consideration to optimize pa-
tients’management. The limitations of our study include the
retrospective observational nature although a strength is repre-
sented by its international design.However, these data highlight
that a multicenter randomized controlled trial is warranted
to assess the efficacy of antifungal prophylaxis in LTRs.
REFERENCES
1. Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections
among organ transplant recipients: results of the Transplant-Associated
Infection Surveillance Network (TRANSNET). Clin Infect Dis. 2010;50:
1101–1111.
2. Yang CH, He XS, Chen J, et al. Fungal infection in patients after liver trans-
plantation in years 2003 to 2012. Ann Transplant. 2012;17:59–63.
6 Transplantation DIRECT ■ 2017 www.transplantationdirect.com
3. Rabkin JM, Oroloff SL, Corless CL, et al. Association of fungal infection
and increased mortality in liver transplant recipients. Am J Surg. 2000;
179:426–430.
4. Liu X, Ling Z, Li L, et al. Invasive fungal infections in liver transplantation. Int
J Infect Dis. 2011;15:e298–e304.
5. Winston DJ, Limaye AP, Pelletier S, et al. Randomized, double-blind trial of
anidulafungin versus fluconazole for prophylaxis of invasive fungal in-
fections in high-risk liver transplant recipients. Am J Transplant.
2014;14:2758–2764.
6. Eschenauer GA, Kwak EJ, Humar A, et al. Targeted versus universal anti-
fungal prophylaxis among liver transplant recipients. Am J Transplant.
2015;15:180–189.
7. Nieto-Rodriguez JA, Kusne S, Mañez R, et al. Factors associated with the
development of candidemia and candidemia-related death among liver
transplant recipients. Ann Surg. 1996;223:70–76.
8. Li C, Wen TF, Mi K, et al. Analysis of infections in the first 3-month after
living donor liver transplantation. World J Gastroenterol. 2012;18:
1975–1980.
9. Cornely OA, Bassetti M, Calandra T, et al. ESCMID* guideline for the diag-
nosis andmanagement of Candida diseases 2012: non-neutropenic adult
patients. Clin Microbiol Infect. 2012;18(Suppl 7):19–37.
10. Bassetti M, Marchetti M, Chakrabarti A, et al. A research agenda on the
management of intra-abdominal candidiasis: results from a consensus
of multinational experts. Intensive Care Med. 2013;39:2092–2106.
11. Friedman ND, Kaye KS, Stout JE, et al. Health care–associated blood-
stream infections in adults: a reason to change the accepted definition
of community-acquired infections. Ann Intern Med. 2002;137:791–797.
12. Dellinger RP, LevyMM, Rhodes A, et al. Surviving Sepsis Campaign: inter-
national guidelines for management of severe sepsis and septic shock,
2012. Intensive Care Med. 2013;39:165–228.
13. Bassetti M, Merelli M, Righi E, et al. Epidemiology, species distribution, an-
tifungal susceptibility, and outcome of candidemia across five sites in Italy
and Spain. J Clin Microbiol. 2013;51:4167–4172.
14. Ng K, Schorr C, Reboli AC, et al. Incidence andmortality of sepsis, severe
sepsis, and septic shock in intensive care unit patients with candidemia.
Infect Dis (Lond). 2015;47:584–587.
15. van Hal SJ, Marriott DJ, Chen SC, et al. Candidemia following solid organ
transplantation in the era of antifungal prophylaxis: the Australian experi-
ence. Transpl Infect Dis. 2009;11:122–127.
16. Marzaban R, Salah M, Mukhtar AM, et al. Fungal infections in liver trans-
plant patients admitted to the intensive care unit. Ann Transplant. 2014;
19:667–673.
17. Bassetti M, Righi E, Ansaldi F, et al. Amulticenter multinational study of ab-
dominal candidiasis: epidemiology, outcomes and predictors of mortality.
Intensive Care Med. 2015;41:1601–1610.
18. Bassetti M, Righi E, Ansaldi F, et al. A multicenter study of septic shock
due to candidemia: outcomes and predictors of mortality. Intensive Care
Med. 2014;40:839–845.
19. Bartoletti M, Giannella M, Caraceni P, et al. Epidemiology and outcomes
of bloodstream infection in patientswith cirrhosis. JHepatol. 2014;61:51–58.
20. Hwang SY, Yu SJ, Lee JH, et al. Spontaneous fungal peritonitis: a severe
complication in patients with advanced liver cirrhosis. Eur J Clin Microbiol
Infect Dis. 2014;33:259–264.
21. Krashin E, Lishner M, Chowers M, et al. Candida albicans in peritoneal
fluid in a patient with hepatic encephalopathy. Isr Med Assoc J. 2015;
17:193–194.
22. Raghuram A, Restrepo A, Safadjou S, et al. Invasive fungal infections fol-
lowing liver transplantation: incidence, risk factors, survival, and impact of
fluconazole-resistant Candida parapsilosis (2003-2007). Liver Transpl.
2012;18:1100–1109.
23. Husain S, Tollemar J, Dominguez EA, et al. Changes in the spectrum and
risk factors for invasive candidiasis in liver transplant recipients: pros-
pective, multicenter, case-controlled study. Transplantation. 2003;75:
2023–2029.
24. Giacobino J, Montelli AC, Barretti P, et al. Fungal peritonitis in patients un-
dergoing peritoneal dialysis (PD) in Brazil: molecular identification, biofilm
production and antifungal susceptibility of the agents. Med Mycol. 2016;
54:725–32.
25. Castanheira M, Messer SA, Rhomberg PR, et al. Antifungal susceptibility
patterns of a global collection of fungal isolates: results of the SENTRYan-
tifungal surveillance program (2013). Diagn Microbiol Infect Dis. 2016;85:
200–204.
26. Shields RK, Nguyen MH, Press EG, et al. Abdominal candidiasis is a hid-
den reservoir of echinocandin resistance. Antimicrob Agents Chemother.
2014;58:7601–7605.
27. Pappas PG, Kauffman CA, Andes DR, et al. Executive summary: clinical
practice guideline for the management of candidiasis: 2016 update by the
infectious diseases society of America. Clin Infect Dis. 2016;62:409–417.
© 2017 Wolters Kluwer Bassetti et al 7
